STOCK TITAN
  1. Home
  2. News
  3. RDHL

Redhill Biopharma Ltd. - RDHL STOCK NEWS

Welcome to our dedicated news page for Redhill Biopharma Ltd. (Ticker: RDHL), a resource for investors and traders seeking the latest updates and insights on Redhill Biopharma Ltd..

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Redhill Biopharma Ltd.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Redhill Biopharma Ltd.'s position in the market.

News
RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights
Rhea-AI Summary
RedHill Biopharma focuses on U.S. government-funded pipeline development in underserved therapeutic areas with opaganib and RHB-107 advancing in externally funded R&D programs. Opaganib shows promise for nuclear and chemical medical countermeasures, Ebola, and COVID-19, while RHB-107 targets COVID-19 and Ebola. Financially, RedHill reports a cash balance of $6.5 million, gross profit of $3.1 million, and operating income of $12.6 million for the year ended December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.89%
Tags
earnings
-
News
RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price
Rhea-AI Summary
RedHill Biopharma (RDHL) announces a registered direct offering with private investors for the purchase and sale of 2,144,487 ADSs and warrants at a premium price of $0.58289 per ADS. The offering represents a 10% premium over the closing price on March 28, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.64%
Tags
offering
-
News
RedHill Announces New USPTO Patent Covering Talicia® Through 2034
Rhea-AI Summary
RedHill Biopharma Ltd. announces the issuance of a new U.S. patent covering Talicia as an all-in-one treatment for H. pylori infection, providing protection until February 2034. Talicia is the only FDA-approved rifabutin-containing therapy for H. pylori eradication, with an optimized resistance profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.77%
Tags
none
News
RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs
Rhea-AI Summary
RedHill Biopharma's opaganib selected by U.S. government for evaluation as a medical countermeasure against Sulfur Mustard exposure. Opaganib, a novel oral small molecule, shows promise for multiple indications including COVID-19 and oncology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.02%
Tags
none
-
News
RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication
Rhea-AI Summary
RedHill Biopharma Ltd. (RDHL) announces promising results of opaganib in treating radiation-induced lung inflammation and fibrosis. Opaganib, a selective SPHK2 inhibitor, significantly improved long-term survival in an in vivo mouse model post ionizing radiation exposure. The data suggest its potential as a medical countermeasure for radiation and cancer therapy. Opaganib is being evaluated for Acute Radiation Syndrome (ARS) and other indications like COVID-19, ARDS, filoviruses, and oncology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.64%
Tags
none
-
News
RedHill Biopharma Announces Closing of $8 Million Registered Direct Offering
Rhea-AI Summary
RedHill Biopharma Ltd. (NASDAQ: RDHL) has closed a registered direct offering for the purchase and sale of 10,000,000 of the Company's American Depositary Shares at a purchase price of $0.80 per ADS, with gross proceeds of $8 million. The Company also issued unregistered warrants to purchase up to 10,000,000 ADSs at an exercise price of $1.00 per ADS. The net proceeds will be used for general working capital, acquisitions, research and development, and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.62%
Tags
offering
News
RedHill Biopharma Announces $8 Million Registered Direct Offering
Rhea-AI Summary
RedHill Biopharma Ltd. (Nasdaq: RDHL) has entered into agreements for the purchase and sale of 10,000,000 of the Company's American Depositary Shares at a purchase price of $0.80 per ADS in a registered direct offering. Additionally, the Company will issue unregistered warrants to purchase up to 10,000,000 ADSs at an exercise price of $1.00 per ADS. The closing of the offering is expected to occur soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-39.81%
Tags
offering
-
News
RedHill Announces New USPTO Patent Grant for Talicia® for H. pylori Treatment Through 2042
Rhea-AI Summary
RedHill Biopharma Ltd. announces the issuance of a new patent by the USPTO covering Talicia as a method for eradicating H. pylori regardless of patient BMI, providing protection until May 2042. The patent is supported by previously published data showing Talicia's efficacy was unaffected by elevated BMI. Talicia has been granted market exclusivity for five years under the GAIN Act QIDP designation, in addition to three years' exclusivity granted for its approval under section 505(b)(2). Talicia is the leading branded first-line therapy prescribed by U.S. gastroenterologists for H. pylori eradication, a bacterial infection affecting approximately 35% of the U.S. adult population.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-39.81%
Tags
none
-
News
RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola
Rhea-AI Summary
RedHill Biopharma Ltd. (Nasdaq: RDHL) announces positive in vitro results for investigational drugs opaganib and RHB-107 in combination with remdesivir, showing a distinct synergy in viral inhibition while maintaining cell viability. Opaganib and RHB-107 are expected to be effective against multiple viral targets, including COVID-19 and emerging viral variants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.13%
Tags
none
News
RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
Rhea-AI Summary
RedHill Biopharma Ltd. (Nasdaq: RDHL) has announced that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1) for continued Nasdaq listing. The company maintained a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days, achieving compliance on December 8, 2023. This comes after previously receiving notification that the bid price for the American Depositary Shares (ADSs) had closed below the minimum $1.00 per share requirement for continued listing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.49%
Tags
none
Stock RDHL logo
Redhill Biopharma Ltd.

Nasdaq:RDHL

RDHL Rankings

#5252 Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

RDHL Stock Data

13.56M
3.30B
6.25%
3.05%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Israel
21 Haarbaa St

About RDHL

redhill biopharma is a biopharmaceutical company focused primarily on development of late clinical-stage new, improved and patented formulations of existing drugs. redhill has an experienced management team, board of directors and advisory board based in israel, the us, canada and europe, with successful track record at big and small pharma of bringing patented drugs to the market, as well as extensive managerial, financial, and transactional expertise